ATRIVA Therapeutics

First-in-class inhibitors against respiratory viral infections

Read More
Invest in research to maximize profits!

Projected retail peak sales of Atriva’s MEK inhibitor ATR-002 in the indication “Influenza in high-risk patients”, as per-oral treatment regime over 5 days could be in excess of € 600 Mio without considering pandemic events or additional indications.

Read More

› ‹

1
2

The ATRIVA Approach

Already in 2001 our scientists published a new antiviral mode of action.

Pipeline

ATRIVA aims to develop new antiviral therapies against different respiratory viral infections.

Markets

The target indication for our lead compound ATR-002, is represented by “Influenza in high-risk patients”.

About Us

Learn more about the people from Atriva Therapeutics GmbH.

First-in-class inhibitors against
respiratory viral infections

ATRIVA aims to develop new antiviral therapies against different respiratory viral infections. Founded in 2015, ATRIVA attracted seasoned experts in virology and drug development to form a unique venture targeting the fast and successful validation of a novel approach to fight infectious diseases Inhibitors of certain cellular signaling pathways, the so called “MEK-Inhibitors”, have shown a superior antiviral activity by blocking viral replication. This creates an unprecedented potential for truly efficacious and safe therapeutics against numerous viral infections.

ATRIVA closed a seed financing of € 3 Mn in late 2016. The proceeds of this allows the company to reach clinical development with its lead project ATR-002 for influenza in high-risk patients. We invite you to explore our approach and pipeline presented on this website and encourage you to contact us directly.

Latest News

Atriva adds Dr. Christian Wallasch to its executive management team.

The next generation of antiviral therapies: After successfully passing an important preclinical development milestone for the lead compound ATR-002 in summer 2017, Atriva Therapeutics GmbH adds a seasoned biopharmaceutical executive, Dr. Christi
New article published in "Platform Life Sciences" presenting ATRIVA approach

A new article has been published in the German publication "Platform Life Sciences" written by Prof. Oliver Planz highlighting the ATRIVA approach:

"Die Virusgrippe „Influenza“ zählt zu den akuten Atemwegserkrankungen (ARE).
Invited keynote lecture on ATRIVAs antiviral MEK inhibitor technology presented at the Annual Meeting of the German Pharmaceutical Society (DPhG)

Atriva scientists were invited to give a keynote lecture on their antiviral MEK inhibitor concept at the Annual Meeting of the German Pharmaceutical Society (DPhG).

The meeting entitled „Novel Therapies for Future Challenges“ was held

Contact Form

Links

About Us
Contact
Legal Notice
Data Protection

Address

Atriva Therapeutics GmbH
Christophstr. 32, 72072 Tübingen

+49 (0)7071 8597673
info@atriva-therapeutics.com

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.

Data Protection Rules I Agree